Join the Parkinson's Disease Psychosis group to help and get support from people like you.
Parkinson's Disease Psychosis News (Page 2)
FDA Approves Vyalev for Advanced Parkinson Disease
TUESDAY, Oct. 22, 2024 – The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson disease (PD). Vyalev is the first and only...
Air Pollution Exposure Increases Risk for Parkinson Disease
FRIDAY, Sept. 20, 2024 – Higher exposure to air pollution increases the risk for Parkinson disease (PD), according to a study published online Sept. 16 in JAMA Network Open. Brittany Krzyzanowski,...
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM
WEDNESDAY, Sept. 18, 2024 – For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with reduced risks for incident dementia and Parkinson disease...
Upper GI Mucosal Damage Tied to Later Parkinson Disease Diagnosis
WEDNESDAY, Sept. 11, 2024 – A history of upper gastrointestinal mucosal damage (MD) is associated with a higher subsequent risk for developing Parkinson disease (PD), according to a study published...
Acadia Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for Nuplazid (pimavanserin)
SAN DIEGO--(BUSINESS WIRE)--Jun. 29, 2018-- Acadia Pharmaceuticals Inc. today announced FDA approval of a new capsule dose formulation and a new tablet strength of Nuplazid (pimavanserin) to help in...